BCM
HTGM

BlueCrest Capital Management’s HTG Molecular Diagnostics, Inc. Common Stock HTGM Stock Holding History

BlueCrest Capital Management’s Portfolio HTGM Stock Details HTGM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-84
Closed -$55K – 1939
2018
Q1 		$55K Buy
+84
New +$63.1K ﹤0.01% 1420

Other funds holding HTGM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
PWP
Private Wealth Partners Mill Valley, California $1.3B AUM 26.2% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
BRWA
B. Riley Wealth Advisors Boca Raton, Florida $1.87B AUM 37.01% 1-Year Est. Return
PCM
Perkins Capital Management Wayzata, Minnesota $133M AUM 127.86% 1-Year Est. Return

BlueCrest Capital Management's HTGM Position: Q2 2018 in Review

BlueCrest Capital Management sold out of HTG Molecular Diagnostics, Inc. Common Stock (HTGM) in Q2 2018, closing a stake of 84 shares — an estimated $55K sold.

BlueCrest Capital Management first reported a position in HTGM in Q1 2018 and held it in 1 quarter. The position peaked at $55K in Q1 2018. 44 funds tracked by Wall St. Rank hold HTGM as of Q2 2018.

  • BlueCrest Capital Management reported no remaining HTG Molecular Diagnostics, Inc. Common Stock position as of Q2 2018 after selling out during the quarter.
  • BlueCrest Capital Management sold 84 HTG Molecular Diagnostics, Inc. Common Stock shares in Q2 2018, an estimated $55K.
  • BlueCrest Capital Management first reported a position in HTG Molecular Diagnostics, Inc. Common Stock in Q1 2018 and held it in 1 quarter.
  • BlueCrest Capital Management's HTG Molecular Diagnostics, Inc. Common Stock position peaked at $55K in Q1 2018.
  • 44 funds tracked by Wall St. Rank held HTG Molecular Diagnostics, Inc. Common Stock as of Q2 2018.

Based on BlueCrest Capital Management's 13F filing for Q2 2018, filed 14 Aug 2018.